Discover and read the best of Twitter Threads about #COAPT

Most recents (5)

#COAPT Risk Score for Death or #HeartFailure 🏥

📍Simple risk score using 4 clinical (COPD, #NYHA class, Afib/Aflut, and #CKD)

📍4 #EchoFirst (#LVEF, LVESD, RVSP, and #TR) variables + 1 treatment-related variable (#TEER)

jacc.org/doi/10.1016/j.… @JACCJournals @GreggWStone ImageImageImageImage
Using data from the #COAPT trial, a simple risk score using 4 clinical and 4 Echo parameters + 1 treatment-related variable (#TEER), which provides prognostic insight into the 2-year rates of ☠️ or #HeartFailure 🏥 in patients with symptomatic #HF and severe #FMR

@JACCJournals
There was consistent benefit from TEER with MitraClip across all risk strata

FMR and HF pts are at ⬆️ risk for ☠️ and recurrent HFH, despite best Med Rx & invasive Tx including MV TEER

👉🏻Future studies are needed to externally validate the COAPT risk score in pts with HF & FMR
Read 6 tweets
What are your pearls for assessing the mechanism & severity of #mitralregurgitation by #EchoFirst?

#JACCIMG presents an imaging-based curriculum to review functional #mitralvalve regurgitation for #CardioTwitter.

Follow/share this #Tweetorial! (1/15) bit.ly/3gw5MZ2
#JACCIMG Tweetorial Mitral regurgitation (2/15)

Case 1: What is the pathology shown?
JACCIMG #Tweetorial (3/15)

Shown is an example of flail leaflet of the #mitralvalve at the P2 segment.

Surgical #mitralvalve repair is the gold standard; due to prohibitive risk, the patient underwent successful percutaneous repair #TMVR, guided by 3D #EchoFirst.
Read 15 tweets
@ACCinTouch @AHAScience @JACCJournals @CircAHA 2020 VHD guidelines. Here's a series of tweet-synopsis. First: #TAVR and AS. Key wasn't just Figure 3 but Table 14 where it highlights specifics favoring SAVR vs TAVR. To me it's informative. @AATSHQ @STS_CTsurgery @EACTS @escardio
#3: Primary MR: TEER (E2E repair) #MitraClip is now Class 2A in high or prohibitive pts with "favorable" anatomy. Asymptomatic but LV dysfn DMR is Class 1 for surgery if repair possible @GAilawadiMD @DrMoritzWvB @TsuyoshiKaneko1 @AATSHQ @STS_CTsurgery @ACCinTouch @AHAScience
Read 9 tweets
#ACC19 #LBCT
@PCRonline
1PANACHE: Safety:Efficacy of Neladenoson Bialanate, Partial Adenosine A1 Receptor Agonist, in CHF & Preserved EF: PANACHE RCT

2PIONEER-HF: Initiation of Angiotensin-Neprilysin Inhibition after Acute Decomp CHF: Open-Label Extension of
PIONEER-HF Trial
3 Hopeful Heart Trial: Blended Collaborative Care for Treating ❤️Failure & Comorbid Depression: 12-Month Outcomes

4 CODIACS-QoL: Randomized Trial of Depression Screening After ACS: Comparison of Depression Identification After ACS-QOL & Cost Effectiveness
5 PARTNER 3: #TAVR or SAVR in Low-Risk Patients: Results of the PARTNER 3 Trial

6 Self-Expanding #TAVR or SAVR in Patients at Low Risk of Surgical Mortality

7 Outcomes of #TAVR with Balloon-Expandable Sapien3 Valve in Bicuspid Aortic Stenosis: An Analysis of STS/TVT Registry
Read 12 tweets
(THREAD)

By @rwyeh request, I bring you this brief introduction of joint frailty models and their application in the #COAPT trial...
Please be advised that @graemeleehickey and others are more expert than I am in the direct, real-world application of such models, but here I am, so whatever. Read it, or don’t.
Suppose you’re just reading along in the #COAPT primary paper, found here:

nejm.org/doi/full/10.10…

when you encounter this bumfuzzle:
Read 26 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!